Covering: 1958 to June 2018 Phenyl-γ-valerolactones (PVLs) and their related phenylvaleric acids (PVAs) are the main metabolites of flavan-3-ols, the major class of flavonoids in the human diet. Despite their presumed importance, these gut microbiota-derived compounds have, to date, in terms of biological activity, been considered subordinate to their parent dietary compounds, the flavan-3-ol monomers and proanthocyanidins. In this review, the role and prospects of PVLs and PVAs as key metabolites in the understanding of the health features of flavan-3-ols have been critically assessed. Among the topics covered, are proposals for a standardised nomenclature for PVLs and PVAs. The formation, bioavailability and pharmacokinetics of PVLs and PVAs from different types of flavan-3-ols are discussed, taking into account in vitro and animal studies, as well as inter-individual differences and the existence of putative flavan-3-ol metabotypes. Synthetic strategies used for the preparation of PVLs are considered and the methodologies for their identification and quantification assessed. Metabolomic approaches unravelling the role of PVLs and PVAs as biomarkers of intake are also described. Finally, the biological activity of these microbial catabolites in different experimental models is summarised. Knowledge gaps and future research are considered in this key area of dietary (poly)phenol research.
The self-splicing group II introns are bacterial and organellar ancestors of the nuclear spliceosome and retro-transposable elements of pharmacological and biotechnological importance. Integrating enzymatic, crystallographic, and simulation studies, we demonstrate how these introns recognize small molecules through their conserved active site. These RNA-binding small molecules selectively inhibit the two steps of splicing by adopting distinctive poses at different stages of catalysis, and by preventing crucial active site conformational changes that are essential for splicing progression. Our data exemplify the enormous power of RNA binders to mechanistically probe vital cellular pathways. Most importantly, by proving that the evolutionarily-conserved RNA core of splicing machines can recognize small molecules specifically, our work provides a solid basis for the rational design of splicing modulators not only against bacterial and organellar introns, but also against the human spliceosome, which is a validated drug target for the treatment of congenital diseases and cancers.
The self-splicing group II introns are bacterial and organellar ancestors of the nuclear spliceosome and retro-transposable elements of pharmacological and biotechnological importance. Integrating enzymatic, crystallographic, and simulation studies, we demonstrate how these introns recognize small molecules through their conserved active site. These RNA-binding small molecules selectively inhibit the two steps of splicing by adopting distinctive poses at different stages of catalysis, and by preventing crucial active site conformational changes that are essential for splicing progression. Our data exemplify the enormous power of RNA binders to mechanistically probe vital cellular pathways. Most importantly, by proving that the evolutionarily-conserved RNA core of splicing machines can recognize small molecules specifically, our work puts solid bases for the rational design of splicing modulators not only against bacterial and organellar introns, but also against the human spliceosome, which is a validated drug target for the treatment of congenital diseases and cancers.
Chemotherapeutic drugs disrupt the replication machinery and trigger apoptosis in cancer cells. For example, cisplatin-based chemotherapeutic drugs form a covalent interaction with DNA, causing cancer cell death. However, cancer cells can respond to these drugs by overtaking their effect. This phenomenon is referred to as chemoresistance, one of the main problems in cancer therapies. In this study, we have considered chemoresistance favored by translesion DNA synthesis enzymes, like DNA polymerase ƞ (Pol η). This enzyme allows DNA replication and cancer cell proliferation even in the presence of chemotherapeutic drug-induced damages, like in the case of platinum-containing drugs. Inhibition of Pol η thus represents a promising strategy to overcome drug resistance and preserve the effectiveness of chemotherapeutic drugs. Here, we report the discovery of a novel class of Pol ƞ inhibitors, with 35 active close analogs. Compound 21 (ARN24964) stands out as the best lead inhibitor, with an IC 50 value of 14.7 µM, a good antiproliferative and synergistic effect with cisplatin, and a favorable drug-like profile in terms of its aqueous kinetic solubility, plasma and metabolic stability. Thus, ARN24964 is a promising lead for further structure-based drug design efforts toward developing drugs to solve or limit the issue of drug resistance to platinum-containing drugs in cancer patients.
Tumor–stroma interactions play a critical role in cancer progression, therapeutic resistance, and treatment response. Among stromal components, cancer-associated fibroblasts (CAFs) represent key regulators of tumor growth and survival and have emerged as promising therapeutic targets. In head and neck squamous cell carcinoma (HNSCC), the abundance of CAF-rich stroma contributes to disease progression and limits the efficacy of conventional therapies. Here, we investigated the antitumor activity of the topoisomerase II inhibitor ARN-24139 in Human Papilloma Virus (HPV)-positive HNSCC using three-dimensional monoculture and co-culture spheroid models. Co-culture spheroids containing fibroblasts exhibited significantly greater sensitivity to ARN-24139 than tumor mono-cultures. The acquisition of CAF-like features by fibroblasts was confirmed by α-smooth muscle actin (α-SMA) expression. At the same time, advanced two-photon imaging enabled longitudinal quantification of stromal remodeling within intact 3D spheroids enriched with EGFP-labeled fibroblasts. At sub-lethal concentrations, ARN-24139 induced marked downregulation of α-SMA, indicating stromal reprogramming, which was accompanied by increased DNA damage in adjacent tumor cells. In contrast, conventional topoisomerase inhibition with etoposide failed to reproduce these stromal effects. Collectively, these findings identify a previously unrecognized stromal-modulating activity of ARN-24139 and suggest a dose-dependent dual mode of action involving both CAF depletion and CAF reprogramming. This work highlights the therapeutic potential of targeting tumor–stroma interactions in HPV-positive HNSCC and supports further investigation of ARN-24139 in stromal-rich malignancies.